TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02472145

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Decitabine 20 mg/m^2
Description: Decitabine 20 milligram per square meter (mg/\[m\^2\]) from Day 1, 2, 3, 4 and 5 of a 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine 20 mg/m^2
Description: Decitabine 20 milligram per square meter (mg/\[m\^2\]) from Day 1, 2, 3, 4 and 5 of a 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talacotuzumab 9 mg/kg
Description: Talacotuzumab 9 milligram per kilogram mg/kg on Day 8 and 22 of a 28-day cycle.
Study: NCT01080326

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoscopic Translumenal Omental Patch
Description: The endoscope will be gently advanced through the ulcer. Irrigation with saline will proceed. Then a viable mobile piece of omentum will be identified and pulled into the ulcer. After the omentum is located in the stomach, clips will be used to fix it in place.
Study: NCT03145922

Intervention type: OTHER
Intervention: Observational Study
Description: Observational study utilizing bronchoscopy, and imaging

Intervention type: OTHER
Intervention: Observational Study
Description: Observational study utilizing bronchoscopy, and imaging
Study: NCT03115398

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pedometer-based Walking Program
Description: Patients will be instructed to meet the daily step count goal displayed on their fitness tracker. If goal is not being met, study team will intervene and reinforce the importance of meeting this goal. Intervention will include a conversation with the patient, led by a study coordinator, to identify any challenges present in meeting the prescribed goal. Solutions to such challenges may be offered by the coordinator or necessary provider, such as a dietitian, when applicable.
Study: NCT05395533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant CD20 monoclonal antibody-MMAE conjugte for injection
Description: The dose of the enrolled subjects was increased according to the following 7 dose groups: 0.1mg/kg, 0.5mg/kg, 1.0mg/kg, 1.5mg/kg, 1.8mg/kg, and 2.1mg/kg. (according to the data of the previous study, when the dose climbs to 1.5 mg / kg, there is a serious decline of neutrophils, which shall be subject to the principle of 3 + 3.
Study: NCT00475293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab and CPT-11
Description: Panitumumab will be administered by IV infusion on day 1 of each cycle just prior to the administration of chemotherapy. The starting panitumumab dose is 9 mg/kg~Irinotecan: 350 or 300 mg/m2. day 1~One treatment cycle is defined as the 21 day period following the commencement of treatment with panitumumab + irinotecan plus additional time, as needed, for the resolution of irinotecan-related toxicities
Study: NCT01994421

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Kinesiotape
Study: NCT03334188

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient engagement materials
Description: The intervention is a brief, animated video designed to engage and activate patients around their HFrEF medication prescribing, as well as a HFrEF medication checklist.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: No Intervention--Usual Care
Description: Control for intervention--patient receives care as usual from provider to contrast against intervention arm.
Study: NCT00824629

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Afterloading embryo transfer procedure
Description: Afterloading embryo transfer procedure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Direct embryo transfer procedure
Description: Direct embryo transfer procedure
Study: NCT02727179

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver resection
Description: The investigators perform an anatomical liver resections or wedge resections depending on tumour's location and tumour's characteristics

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Liver resection
Description: The investigators perform an anatomical liver resections or wedge resections depending on tumour's location and tumour's characteristics
Study: NCT01749098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04958242
Description: PF-04958242, 0.35 mg orally administered capsule on Day 1 and 0.25 mg orally administered capsule on Days 2 - 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: At 60 minutes after the 0.25 mg dose of PF-04958242 on Day 5, Ketamine (0.23 mg/kg over 1 minute, followed by a maintenance rate of 0.58 mg/kg/hr for 75 minutes) will be infused.
Study: NCT00493311

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IV Placebo
Description: IV Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Acetaminophen
Description: Intravenous acetaminophen solution 1 g / 100 ml
Study: NCT01749098

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule orally administered on Days 1 - 5

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketamine
Description: At 60 minutes after Placebo on Day 5, Ketamine (0.23 mg/kg over 1 minute, followed by a maintenance rate of 0.58 mg/kg/hr for 75 minutes) will be infused.
Study: NCT02767752

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: T-ChOS

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Capecitabine
Study: NCT00493311

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Reference Standard Endotoxin (RSE)
Description: Administration of Reference Standard Endotoxin (RSE) to induce fever. Applicable to both study arms: Administration of a 1 ng/kg body weight test dose of RSE to test for fever response. Observation period of at least 60 minutes to ensure no exaggerated systemic responses, followed by administration of a 4 ng/kg of RSE to induce fever.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Reference Standard Endotoxin (RSE)
Description: Administration of Reference Standard Endotoxin (RSE) to induce fever. Applicable to both study arms: Administration of a 1 ng/kg body weight test dose of RSE to test for fever response. Observation period of at least 60 minutes to ensure no exaggerated systemic responses, followed by administration of a 4 ng/kg of RSE to induce fever.
Study: NCT04299867

Intervention type: PROCEDURE
Intervention: Bowel Surgery with Metronidazole
Description: Metronidazole will be given per standard of care prior to incision. Intraoperative plasma samples will be obtained from pre-existing vascular access catheters at end of bolus, 30, 60, 90 minutes, at time of intestinal excision(s), and at the end of the case in ethylenediaminetetraacetic acid microcontainers, exceeding no more than approximately 5 mL total.~At the time of intestinal excision, the surgeon will cut at least 500 mg of intestine from the specimen, ensuring all layers of bowel are included. If more than one intestinal sample is taken during the surgery, such as in the case of multiple strictures removed, each sample will be obtained and labeled appropriately.
Study: NCT02767752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Study: NCT04574817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HX008
Description: 200 mg administered as IV infusion on Day 1 of each 21-day cycle.
Study: NCT00844337

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gentamicin & Amoxicillin x 7days
Description: Injectable gentamicin once daily and oral amoxicillin twice daily for seven days.~The dose for gentamicin is 4 - 5 mg/kg/24 hours. The dose for amoxicillin is 90-115 mg/kg/day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Penicillin & gentamicin x 2 d + Amoxicillin X 5 d
Description: Injectable penicillin and gentamicin once daily for two days followed by oral amoxicillin twice daily for five days. The dose for penicillin is 40,000 - 50,000 U/kg/24 hours, the dose for gentamicin is 4 - 5 mg/kg/24 hours, and the dose for amoxicillin is 90-115 mg/kg/day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard reference therapy
Description: Injectable procaine-benzyl penicillin and gentamicin once daily each for seven days. The penicillin dose is 40,000 - 50,000 U/kg/24 hours, and the gentamicin dose is 4 - 5 mg/kg/24 hours.
Study: NCT01234415

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rhinoplasty
Description: Rhinoplasty is performed under general anaesthesia; the duration is 1 to 2 hours. The surgical approach for implantation of the biomaterial is external rhinoplasty. The incision is made at the columella (base of nose) and becomes internal for the scar to be as unobtrusive as possible. The septum skeleton is then destroyed in order to place the synthetic biomaterial. The biomaterial is remodelled in order to have a natural external aspect of the nose. The incision is closed and the wicks are put in place in the nose for 4 days. A cast and a sticker will be put in place after surgery to maintain properly the biomaterial.
Study: NCT03109236

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GCSF
Description: 5 doses of GCSF injection will be injected under the skin on the abdomen to mobilize the bone marrow cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GCSF
Description: 5 doses of GCSF injection will be injected under the skin on the abdomen to mobilize the bone marrow cells.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CD133 Cells Transplantation
Description: Endothelial progenitor cells are harvested by CD133+ MACS (magnetic activated cell sorting) sort selection of bone marrow and a minimum of 1x 10\^6 and up to 50-100 x 10\^6 cells are transplanted to one lobe of the liver via a percutaneous catheter inserted into the portal venous system by percutaneous transhepatic approach for engraftment.
Study: NCT02595099

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness training
Description: group-based training programme, 2.5 hours delivered weekly for 8 weeks
Study: NCT01715883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Nitrite
Description: Same as the details in Arm Description.
Study: NCT02975102

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CBL-101 Eye Drops
Description: CBL-101 Eye Drops 3 to 6 times per day for 3 months.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vismed® Multi Eye Drops
Description: Vismed® Multi 3 to 6 times per day for 3 months.
Study: NCT04038242

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resilience promotion program
Description: Resilience Promotion Program consists of eight sessions. Except the first orientation session and the last review session, other six sessions focus on cultivating the five internal resiliency factors (physical, behavioral, cognitive, emotional and spiritual). There are two sessions for behavioral factor, including one special to deal with the relationships between parents and children.
Study: NCT00780455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon beta-1b, FRP within 15 days after randomization
Description: Treatment by Interferon beta-1b (Betaseron, BAY86-5046) for 3 month and beginning of the Functional Rehabilitation Program starting within 6 weeks after randomization

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon beta-1b, FRP about 6 weeks after randomization
Description: Treatment by Interferon beta-1b (Betaseron, BAY86-5046) for 3 month and beginning of the Functional Rehabilitation Program about 6 weeks after randomization.
Study: NCT02146209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole benzoate
Description: Single oral dose of 400 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flagyl 125 mg/5 ml oral suspension
Description: Single oral dose of 500 mg (20 ml suspension)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flagyl 400 mg Tablets
Description: Single oral dose of 400 mg
Study: NCT00738855

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral Gastrografin
Description: 100 ml of the dye administered through a nasogastric tube
Study: NCT02798497

Intervention type: OTHER
Group type: OTHER
Intervention: Serum and Blood samples

Intervention type: OTHER
Group type: OTHER
Intervention: Serum and Blood samples
Study: NCT00738855

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Nothing per os
Description: A nasogastric tube
Study: NCT00879775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Intravenous injection of caffeine 200mg with 100ml of normal saline over 1 hour, once a day, for two days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Intravenous injections of 100ml of normal saline over 1 hour, once a day, for two days
Study: NCT03431753

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PSA, STHLM3 and mpMRI for PC detection
Description: Men who request a prostate specific antigen test from their general practitioner will be offered study participation.~Men with increased PC risk as judged from the STHLM3 test and/or an elevated PSA test will be offered an mpMRI examination.
Study: NCT00961506

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LESS cholecystectomy
Description: LESS cholecystectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic cholecystectomy
Description: laparoscopic cholecystectomy
Study: NCT02467439

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Notification cards
Description: detection of AHI, contract partner notification, and social contact referral to find persons unaware of their HIV infection.
Study: NCT00927173

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Brainsway H-Coil Deep TMS System
Description: Deep Transcranial Magnetic Stimulation (DTMS) is a new form of TMS which allows direct stimulation of deeper neuronal pathways than the standard TMS. The H-coil is a novel DTMS coil designed to allow deeper brain stimulation without a significant increase of electric fields induced in superficial cortical regions

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Brainsway H-Coil Deep TMS System (Sham treatment)
Description: In the sham treatment,the electrical field induced by the sham coil cannot invoke any action potentials and if no action potentials are induced, then the electric field is insignificant and there is no treatment effect on the brain.
Study: NCT03544294

Intervention type: DEVICE
Intervention: Xience alpine, ultimaster, resolute onyx, synergy
Description: PCI will be performed
Study: NCT05040347

Intervention type: OTHER
Intervention: test NETs markers
Description: NETs markers (Myeloperoxidase, Neutrophil elastase, Citrate histone H3) and anti-β2 glycoprotein I were detected in plasma using capture ELISA and specific ELISA kits.

Intervention type: OTHER
Intervention: test NETs markers
Description: NETs markers (Myeloperoxidase, Neutrophil elastase, Citrate histone H3) and anti-β2 glycoprotein I were detected in plasma using capture ELISA and specific ELISA kits.
Study: NCT03435627

Intervention type: DRUG
Intervention: Somatropin
Description: Participants will be treated with commercially available Norditropin® (somatropin) according to routine clinical practice at the discretion of the treating physician.

Intervention type: DRUG
Intervention: Somatropin
Description: Participants will be treated with commercially available Norditropin® (somatropin) according to routine clinical practice at the discretion of the treating physician.
Study: NCT03416478

Intervention type: DIAGNOSTIC_TEST
Intervention: ctDNA test
Description: ctDNA test to find some possible mutation.
Study: NCT00699023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ezetimibe tablets
Description: ezetimibe tablets 10 mg/die

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simvastatin tablets
Description: simvastatin tablets 20 mg/die

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: simvastatin tablets
Description: simvastatin tablets 20 mg/die

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT05795972

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: inulin
Description: patients treated with standard therapy with a supplementation of Inulin 6g twice a day for 3 months.
Study: NCT05040347

Intervention type: OTHER
Intervention: test NETs markers
Description: NETs markers (Myeloperoxidase, Neutrophil elastase, Citrate histone H3) and anti-β2 glycoprotein I were detected in plasma using capture ELISA and specific ELISA kits.
Study: NCT01261000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegvisomant
Description: Pegvisomant used as indicated
Study: NCT05795972

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard therapy
Description: control group (patients treated also with standard therapy)
Study: NCT00339833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salsalate
Description: The intervention was salsalate (3g/day) for 7 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical placebo for 7 days.
Study: NCT01942876

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quit Using Drugs Intervention Trial
Description: The goal of the Quit Using Drugs Intervention Trial (QUIT) is to conduct a small RCT of a primary care clinic-based very brief intervention protocol for reducing the use of illegal drugs and the occurrences of drug-related harm in low-income, racially-diverse patient populations at two 'safety-net' clinics in Los Angeles. The design will emphasize screening, very brief clinician advice, and telephone drug-use health education to reduce 'at risk' drug use and thus interrupt progression from casual or episodic abuse to dependence.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Health behavior maintenance
Description: This attention-control arm will receive a sham telephone intervention of equivalent duration on health behavior maintenance.
Study: NCT03891355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone
Study: NCT03019640

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Undergo stem cell transplant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustine
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cord Blood-derived Expanded Allogeneic Natural Killer Cells
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study: NCT02225262

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CyberKnife Radiosurgery
Description: 36.25 Gy delivered in 5 fractions of 7.25 Gy per fraction
Study: NCT01357395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amuvatinib
Description: Amuvatinib 300 mg PO TID
Study: NCT05055154

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Very low calorie diet
Description: In hospital patients will eat prepared diet with 567 kcal a day during 3 weeks
Study: NCT02609672

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: A biomechanical exercise program shown to decrease joint loading was administered 3 times a week for 12 weeks. Outcomes included mobility performance; pain; strength; cardiovascular fitness; and resilience.

Intervention type: OTHER
Group type: OTHER
Intervention: No Exercise
Description: A no exercise (control) group maintained their existing activity level for 12 weeks. Outcomes included mobility performance; pain; strength; cardiovascular fitness; and resilience.
Study: NCT02860897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Premarin
Description: Vaginal estrogen cream

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vagifem
Description: Vaginal estrogen tablet
Study: NCT03266718

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Physical Activity Intervention
Description: To develop and test a couple-based physical activity intervention among cancer survivors and their partners

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Physical Activity Intervention
Description: To develop and test a couple-based physical activity intervention among cancer survivors and their partners
Study: NCT03689842

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Uterine transplantation
Description: Uterine transplantation from living donor
Study: NCT02282553

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetically steerable pill camera (Microcam Navi, Intromedic Ltd, Seoul, Korea)
Description: Capsule endoscopy uses a swallowable pill camera which passes through the GI tract by the action of peristalsis. The procedure utilizes a battery powered wireless capsule to transmit images of the gastrointestinal tract as it passes through the small intestine. The images are later downloaded to a computer and reviewed by a trained physician. Magnetically steerable gastric capsule endoscopy uses a pill camera containing a small amount of magnetic material, that can be manoeuvred in the gut and intestine by the physician using a handheld magnet.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flexible endoscope
Description: The current standard for investigation of upper gastrointestinal disorders is flexible endoscopy; oesophagogastroduodenoscopy (OGD), also known as gastroscopy.
Study: NCT03377686

Intervention type: DIAGNOSTIC_TEST
Intervention: inflammation markers in exhaled breath
Description: non-invasive, cross-sectional, assessment of inflammation markers in exhaled breath with various techniques (observational)

Intervention type: DIAGNOSTIC_TEST
Intervention: inflammation markers in exhaled breath
Description: non-invasive, cross-sectional, assessment of inflammation markers in exhaled breath with various techniques (observational)

Intervention type: DIAGNOSTIC_TEST
Intervention: inflammation markers in exhaled breath
Description: non-invasive, cross-sectional, assessment of inflammation markers in exhaled breath with various techniques (observational)